Cadherins are a family of transmembrane glycoproteins that mediate Ca 2 þ -dependent homophilic cell-cell adhesion and play a crucial role in cell differentiation. E-cadherin-mediated cell-cell adhesion is lost during the development of most epithelial cancers. This study examines cadherin-dependent adhesion in cell lines derived from rhabdomyosarcoma (RMS), a highly malignant softtissue tumor committed to the myogenic lineage, but arrested prior to terminal differentiation. We analysed the expression of cadherins and associated catenins at the mRNA and protein levels as well as their localization in nine RMS-derived cell lines relative to normal myoblasts. We show a decrease in the expression of cadherins and catenins in all RMS-derived cell lines compared to control cells. This decrease in the expression of N-and M-cadherin was confirmed in RMS biopsies. In contrast, R-cadherin is found expressed in RMS, whereas it is normally absent in normal myoblasts. We show that a decrease of R-cadherin expression using RNA interference inhibits cell proliferation of the RD cell line. In addition to their diminished expression, cadherins and catenins do not localize to intercellular contacts in embryonal RMS (ERMS), whereas specific persistent localization is seen in alveolar RMS (ARMS)-derived cell lines. Thus, RMS exhibit defects in the expression of molecules of the cadherin family. Defects in the localization of these adhesion molecules at the sites of cell-cell contact are specifically observed in the ERMS subtype. In addition, our data suggest that R-cadherin is a specific diagnostic marker for RMS and is also an important factor of RMS cell proliferation.
Introduction
Rhabdomyosarcomas (RMS) are highly malignant tumors of skeletal muscle origin, accounting for 5-10% of childhood cancers and for more than 50% of pediatric soft-tissue sarcoma (Merlino and Helman, 1999) . They are thought to arise as a consequence of regulatory disruption of the growth and differentiation of skeletal muscle precursor cells, hence they show some characteristics of skeletal muscle. Indeed, rhabdomyoasarcoma cells express MyoD and/or Myf5 but the ability of MyoD to activate the myogenic program is repressed in RMS (Tapscott et al., 1993) . Two major subtypes have been defined based on both histological and molecular/genetic markers (Scrable et al., 1989) . Embryonal rhabdomyosarcoma (ERMS) are comprised of spindle-shaped cells. They are characterized by loss of heterozygosity at the 11p15 locus, which is associated with loss of maternal and duplication of paternal chromosomal materiel as well as loss of heterozygosity at chromosome 16 (Besnard-Guerin et al., 1996; Visser et al., 1997) . Approximately two-thirds of all RMS are embryonal. Alveolar rhabdomyosarcoma (ARMS) are comprised of small round densely packed cells. They are characterized by a reciprocal translocation between chromosome 2q35 and 13q14 or 1q36 and 3q14. This generates a fusion protein between the 5 0 DNAbinding domain of PAX3 or PAX7, members of the Paired Box transcription factor family to the transactivation domain of FKHR, a member of the forked/HNF-3 transcription factor family (Fredericks et al., 1995; Barr, 1999) . Other genetic alterations have been described in RMS, such as mutations in p53, N-ras and K-ras and overexpression of N-myc, IGF2 and c-Met (Chardin et al., 1985; Garson et al., 1986; Stratton et al., 1989; Malkin et al., 1990; Wexler and Helman, 1994; Zhan et al., 1994; Ferracini et al., 1996; Zhang et al., 1996) . are already metastatic at the first examination (Sommelet et al., 1998) . In addition to genetic or epigenetic events involved in tumor invasion, the loss of cell-cell adhesion is one rate-limiting step for cancer progression (Takeichi, 1993) . Several groups demonstrated that expression of E-cadherin, the prime mediator of intercellular adhesion in epithelial cells, is often lost in epithelial cancers (Christofori and Semb, 1999) . Cadherins are highly conserved calcium-dependent transmembrane glycoproteins that mediate homo-typic cell-cell adhesion through their extracellular domain. Cadherin cytoplasmic domains provide F-actin cytoskeleton attachment points through the association of catenins and other cytoskeletal associated proteins (Kemler, 1993) . The cadherin is directly associated with b-catenin or g-catenin (also known as plakoglobin). Both of these proteins interact with acatenin, which links the cadherin/catenins complex to the actin cytoskeleton. These adhesive receptors are likely to regulate diverse functions beyond the basic adhesive process, such as various intracellular signaling events (Fukata and Kaibuchi, 2001) . Developing skeletal muscle expresses N-, M-, R-and 11-cadherin and cadherin-dependent adhesion is required for a variety of cellular events during skeletal myogenesis (Knudsen, 1990) . Cadherin-11 is only weakly expressed in developing muscles and is essentially found in mesenchymal cells in the distal portion of the limb and the sclerotome cells in the somites. Cadherin-11 expression is downregulated in differentiated structures (Kimura et al., 1995) . N-cadherin is expressed early in somites, the myotome and limb buds, and downregulated as synaptogenesis and secondary myogenesis proceed (Duband et al., 1987; Hatta et al., 1987; Linask et al., 1998) . N-cadherin-dependent intercellular adhesion has a major role in cell cycle exit and in the induction of the skeletal muscle differentiation program (Goichberg and Geiger, 1998; Charrasse et al., 2002) . In contrast to N-cadherin, which is expressed by Pax3-positive migrating myogenic precursors, M-cadherin is expressed later and only by Pax3-negative committed precursors. Its expression increases at the onset of secondary myogenesis. M-cadherin has been implicated in terminal myoblast differentiation and particularly in myoblast fusion (Zeschnigk et al., 1995) . R-cadherin is detected in the somites and the limbs, and is localized at cell-cell contacts of primary myoblasts during primary myogenesis, as well as at the primary myotube/secondary myoblast boundaries during secondary myogenesis (Rosenberg et al., 1997) . R-cadherin expression is lost in adult muscles.
In order to identify molecules that are absent or specifically expressed in RMS tumor cells, we have examined the expression of cadherins and catenins. Our results demonstrate an overall decrease in the expression of N-and M-cadherins and catenins in RMS cell lines at both the mRNA and protein levels. In addition, RMS biopsies display a similar decrease in N-and M-cadherin expression. In contrast, R-cadherin is specifically expressed in RMS. We further demonstrate that a decrease of R-cadherin by siRNA slows down the proliferation rate of RMS cells. In addition, we observe clear defects in the cellular localization of cadherins and catenins molecules in all ERMS but not ARMS-derived cell lines.
Results

Cadherins expression in cell lines derived from human RMS and biopsies
We examined the expression of three cadherins (N, M and R) known to be involved in various steps of skeletal myogenesis in control myoblasts (human, mouse and rat), in nine cell lines isolated from RMS and biopsies of RMS. Owing to the difficulty in obtaining different human control myoblasts, we have also used normal mouse and rat ones. Real-time quantitative PCR revealed a decrease in both N-and M-cadherin mRNA levels in almost all RMS cell lines in comparison to human (MH), mouse C2C12 and rat L6 control myoblast cell lines, except for N-cadherin, which is not expressed in L6 myoblasts (Figure 1a and b) . In contrast, R-cadherin mRNA, which is absent from control cells and ARMS, is detected in four ERMS (Figure 1c) . We also extended this analysis by examining these cadherins in biopsies of RMS with a ratio of tumoral cells versus stromal-nontumoral cells higher than 80% (Figure 2 ). Nine ERMS and nine ARMS were analysed. Again we observe a decrease in both N-and M-cadherin mRNA levels in comparison to control myoblasts. This decrease is even more marked than the one observed in Figure 1 with the RMS cell lines. In addition, R-cadherin mRNA is found in ERMS and also ARMS, but not in control myoblasts.
We next examined cadherin expression by immunoblot analysis. Figure 3 shows a correlation between the RT-PCR and immunoblot data. Indeed, both N-and M-cadherin protein levels decreased in RMS cell lines relative to control ones. In three cell lines , no N-cadherin was detected. Again, Rcadherin is found expressed in four ERMS, but totally undetectable in both control and ARMS cell lines. Immunodetection of a-tubulin showed that equal amounts of protein were present in each lane.
Thus, RMS cell lines show a decrease in the expression level of both N-and M-cadherins. In addition, the expression of R-cadherin is detected in ERMS cell lines. RMS biopsies' analysis confirms, at the mRNA level, the decease in N-and M-cadherins. In contrast, R-cadherin is found expressed in both ERMS and ARMS biopsies.
Catenin expression in cell lines derived from human RMS
We next examined the expression of catenins (a-, b-, gand p120) in all these cell lines by immunoblot analysis. As shown in Figure 4 , the cell lines we have tested express different levels of a-, b-, g-and p120 catenins. We quantified their expression relative to a-tubulin, by densitometric analysis of the immunoblots. g-Catenin is strongly diminished in almost all RMS cell lines and undetectable in the cell lines, A-204, SJRh30 and JR/C. We also observed a decrease in a-, b-and p120 catenins expression in almost all RMS cell lines in comparison to control myoblasts. Thus, RMS cell lines show a slight decrease in the expression level of a-, b-and p120 catenins and a marked decrease in the expression level of g-catenin.
Cadherin and catenin localization in cell lines derived from human RMS In addition to expression defects, abnormal distribution of cadherin/catenin proteins might lead to defects in cell-cell adhesion. We thus analysed the distribution of N-and M-cadherin as well as that of a-, b-, g-and p120 catenins by immunocytochemistry. Figure 5 shows the summary of five independent experiments and indicates the percentage of cells having cadherins or catenins correctly localized at the cell-cell contact sites. While Ncadherin is expressed in RD and A-673 cell lines, it did not clearly localize at the cell-cell contact sites, with less than 5% displaying faint N-cadherin staining at these sites. In contrast, N-cadherin is found localized at the cell-cell contact sites in ARMS cell lines. Between 70 Taken together, these data reveal that ERMS and ARMS show different localization of N-and Mcadherin, as well as a-, b-, g-and p120 catenin, at the sites of cell-cell contact.
R-cadherin silencing decreases RD cell proliferation
In order to analyse the direct involvement of R-cadherin in RMS proliferation, we used RNA interference technology to inhibit R-cadherin expression in the RD cells that are the most transfectable RMS-derived cell lines. Preliminary experiments performed using different concentration of the pSUPER plasmid delivering the siRNA and different expression time allowed us to establish the best conditions for the R-cadherin gene silencing efficiency (data not shown). R-cadherin gene silencing was analysed by Western blot (Figure 9a ). Densitometry analysis revealed that R-cadherin protein level was progressively reduced by RNAi and reached maximal inhibition (80%) after 4 days. N-cadherin and tubulin protein expression levels were unaffected demonstrating the specificity of the RNAi.
To determine whether R-cadherin gene silencing affected RD cell proliferation, we have performed BrdU incorporation in RD cells expressing R-cadherin RNAi. As shown in Figure 9b , R-cadherin gene silencing decreased cell proliferation of RD cells as measured by BrdU incorporation 4 days after transfection. Indeed, quantification of these results shows that the expression of empty vector or vector delivering unrelated siRNA led to 52 and 55% BrdU incorporation, whereas Rcadherin siRNA reduced BrdU incorporation to 12%.
Thus, these data suggest that R-cadherin is involved in RMS cell proliferation
Discussion
Skeletal myogenesis is a multistep process regulated temporally and spatially in the embryo, which involves cell-cell adhesion at various steps. RMS is a highly We observe aberrant expression of these cell-cell adhesion molecules in all cell lines tested, suggesting deficient intercellular adhesion that could lead to problems in the growth arrest and the myogenic program engagement, thus favoring cancer development. Our data also reveal specific R-cadherin expression in the RMS, hence providing a potential novel marker for these tumors. In addition, inhibition of Rcadherin expression decreases cell proliferation of the RD cell line. Finally, the failure of cadherins and catenins to localize at the sites of cell-cell contacts in ERMS, but not ARMS, is one characteristic of ERMS.
Cadherin and catenin expression in RMS
Tumor cells often show a decrease in cell-cell and/or cell-matrix adhesion. An increasing body of evidence now indicates that aberrant cell adhesion is causally involved in tumor progression and metastasis, rather than merely being a consequence of it (Nollet et al., 1999) . Around 85% of human cancers originate from epithelial cells, thus most of the available data concern E-cadherin. Numerous studies reveal that multiple mechanisms lead to E-cadherin inactivation, including both genetic and epigenetic events (mutations in the E-cadherin gene, loss of heterozygosity on 16q where the E-cadherin gene is found, transcriptional inactivation by DNA methylation around the promoter region) (Suzuki et al., 1996; Chalmers et al., 2001 ) (Christofori and Semb, 1999) . In addition, alterations of catenin expression in human cancers have been reported that led to the decrease in E-cadherin-mediated cell adhesion . A previous study only performed in two RMS cell lines also show defects in N-cadherin and a-and b-catenin expression (Soler et al., 1993) . We have analysed cadherin-mediated cell adhesion in RMS, nonepithelial tumors of skeletal muscle origin, and found multiple defects in the expression of cadherins and catenins in RMS-derived cell lines. Different mechanisms might be involved in this decrease in cadherin and catenin expression. In particular, the altered expression and/or activity of transcription factors, which regulate the promoters of the adherens junction proteins, might cause these expression defects. Slug and Snail, two zinc-finger transcription factors, decrease E-cadherin promoter activity in cancers . Additionally, CpG hypermethylation of the E-cadherin promoter is an important mechanism of E-cadherin gene inactivation (Nojima et al., 2001; Ribeiro-Filho et al., 2002) .
Cadherin molecules play important roles during skeletal myogenesis and their loss of expression and/or localization might affect myogenesis at different levels. N-cadherin-mediated adhesion is involved in myogenic induction (George-Weinstein et al., 1997; Goichberg and Geiger, 1998) . Indeed, cell-cell contacts formed via the N-cadherin trigger signaling events that promote the commitment to myogenesis, in particular through the regulation of Rho GTPase activity . The decrease in N-cadherin-mediated adhesion, arising as a consequence of either expression or localization defects, might thus lead to aberrant signaling normally controlled by the activation of this adhesive receptor. Along this line, we have previously described a strong activation of endogenous Rac1 and Cdc42Hs in three RMS cell lines , whereas these activities are normally decreased by Ncadherin-mediated adhesion . Mcadherin has been implicated in terminal differentiation and particularly in myoblast fusion (Zeschnigk et al., 1995) . The decrease in M-cadherin-mediated adhesion might be responsible for the absence of cell fusion and myotube formation observed in RMS or might illustrate the early differentiation block in the normal myogenic program.
It will be interesting to analyse the growth and myogenic potential of RMS-derived cell lines after the expression of cadherin/catenin molecules. Until now, attempts to induce the myogenic program in RMS have focused on the alteration of growth factor activity. Indeed, many autocrine loops are often involved in regulating proliferation and/or differentiation in transformed cells (El-Badry et al., 1990; Bouche et al., 2000) . Inhibition of single autocrine loop (EGF, IGF, TGFb, HGF/SF) in RMS induces growth arrest, but does not lead to muscle differentiation (Kalebic et al., 1994; Minniti et al., 1994) . Blockade of all autocrine loops with suramin, a molecule that nonselectively interferes with the binding of growth factors to their cellular receptors, inhibits the growth of human RMS and produces a slight increase in myogenic differentiation in some RMS (De Giovanni et al., 1995) . Successful myogenic induction in RD cells was obtained by inducing p38 MAPK activation (Puri et al., 2000; Ostrovsky et al., 2002) or the gap junction protein connexin 43 (CX43) expression (Proulx et al., 1997) . p38 MAPK activation in RD cells stimulates latent MyoD, which becomes able to stimulate muscle-specific gene expression and to suppress cell growth. N-cadherin is involved in pathways regulating MyoD (Gauthier et al., 1996; Carnac et al., 1998; Charrasse et al., 2002) , thus it will be interesting to determine whether N-cadherin expression in RMS might be able to induce myogenesis. The expression of CX43 in RD cells induces a marked decrease in cell proliferation, as well as a marked increase in cell membrane fusion and myosin expression. Interestingly, functional connections have been described between connexin and cadherin molecules (Prowse et al., 1997; Ko et al., 2000) .
Differential cadherin and catenin localization in ERMS and ARMS
Our data demonstrate important differences in localization of cadherins and catenins between ERMS and ARMS, suggesting the existence of mechanism(s) specific for ERMS that govern cadherin/catenin mislocalization. These two major categories of RMS are characterized by distinct genetic markers (Merlino and Helman, 1999) . ERMS present a LOI at the 11p15 locus, which contributes to the IGF2 overexpression observed in these tumors. Nevertheless, IGF2 overproduction is also observed in ARMS, most probably as a consequence of p53 mutations, as p53 inhibits transcription of the IGF2 gene (Zhang et al., 1996) . Autocrine loops are often involved in regulating proliferation and/or differentiation. Transforming growth factor b (TGFb), a wellknown myogenesis inhibitor, is overproduced in RMS (Bouche et al., 2000) . Ras, a potent myogenesis inhibitor, is found activated in RMS (Chardin et al., 1985; Meriane et al., 2002) . Aberrant c-met signaling has been involved in the development of RMS (Ferracini et al., 1996) . c-met activation allows myogenic precursor migration and satellite cell proliferation. Deregulated cmet, TGFb and Ras signaling are all involved in the loss of cell-cell adhesion, leading to aberrant cell migration and deregulated growth (Ridley et al., 1995; Potempa and Ridley, 1998) . It is interesting to note that transgenic mice expressing the c-met transgene in the Ink4a/Arf À/À background develop malignant RMS, thus providing a mouse model of RMS in which cadherinmediated adhesion might be studied (Sharp et al., 2002) . However, neither of these events seems to be specific for ERMS. Further studies will be required to identify the mechanisms involved in cadherin/catenin delocalization in ERMS. Nevertheless, cadherin/catenin localization might be a useful tool to discriminate between ERMS and ARMS, which is still an area of active research (Pohar-Marinsek et al., 2002) .
The undercoat proteins of the catenin family have a different function in the cadherin-mediated cell adhesion system. They connect cadherins to actin filaments and allow firm cell-cell adhesion. Catenins might also have cytoplasmic and nuclear functions. Indeed, b-catenin has been shown to function as a downstream transcriptional activator of the Wnt/Wingless signaling pathway during morphogenesis and/or tumorigenesis . No b-catenin accumulation in the nucleus was detectable in the RMS cell lines tested. p120 catenin localization seems to control Rho GTPases activity; cytoplasmic p120 increases Rac1 and Cdc42 activities, which might in turn participate in adherens junction disassembly (Noren et al., 2000) . p120 was also detected in the nucleus, where it interacts with Kaiso, a zing-finger-containing transcription factor (Daniel and Reynolds, 1999) . While our data demonstrate cytoplasmic p120 localization in ERMS, no detectable nuclear accumulation was detected.
R-cadherin expression in ERMS
Even though the role of R-cadherin during skeletal myogenesis is still unknown, its expression has been detected during primary myogenesis and at the primary myotube/secondary myoblast boundaries. In any case, R-cadherin is no longer expressed in adult tissues, except in the brain (our personal observations (Rosenberg et al., 1997) ). R-cadherin expression in RMS cell lines suggests that R-cadherin expression has been maintained due to the development stage of RMS or that this protein has been re-expressed in these transformed cells. Nevertheless, this protein seems to play a role in RMS cell proliferation, since we show that R-cadherin inhibition in RD cells decreases their proliferation. R-cadherin expression in RMS may be of diagnostic value as it is absent from normal cells. Since R-cadherin is expressed in embryonic skeletal muscle, this protein should be a more sensitive marker than structural proteins such as desmin or actins. Although published data support the view that MyoD and myogenin expression are highly specific for rhabdomyoblastic differentiation, their expression has also been reported in rare tumors with rhabdomyoblastic differentiation, including Wilms tumors (Wang et al., 1995) , neuroendocrine carcinoma , malignant glial tumors (Marucci et al., 2000) , ectomesenchymona and nephroblastoma (Kumar et al., 2000) . Analysis of R-cadherin expression in these tumors would reveal if it is a useful marker to differentiate RMS from other malignant, small round cell tumors of childhood.
Finally, R-cadherin expression in RMS suggests that immunotherapy might become a specific and effective therapeutic option for these diseases.
RMS are aggressive malignant tumors that develop very rapidly, which suggest that the genetic aberrations and perturbations associated with these childhood malignancies must be less complicated than carcinomas. Nevertheless, it seems that the impairment of cadherinmediated adhesion is a common defect in all RMS tested, which might help explain the rapidity of this malignancy and metastatic properties.
Materials and methods
Cell lines
C2C12 mouse myoblasts (from the American Type Culture Collection (ATCC)), L6 rat myoblasts (Vandromme et al. , 1992) and human myoblasts (MH) from striated paravertebral muscle (Banque de tissus pour la recherche, AFM-BTR) were grown in Dulbecco's modified Eagle's medium (DMEM)/ HAM F-12 (ratio 1 : 1) supplemented with 10% FCS (HyClone).
The embryonal rhabdomyosarcoma cell lines (ERMS) RD, A-204 and A-673 were purchased from the ATCC. The ERMS cell lines CT-10 and TTC-442 were kindly provided by T. Triche (Childrens Hospital Los Angeles, USA).
The alveolar rhabdomyosarcoma cell lines (ARMS) SJRH30 were from the ATCC, the Rh30 and Rh28 cell lines were kindly provided by P Houghton (St Jude Childrens Hospital, Memphis, USA) and the JR/C cell line was kindly provided by J Garvin (Medical University of South Carolina, Charleston, USA). All these ARMS cell lines contain the PAX-FKHR fusion protein. These cell lines were grown in DMEM with 10% FCS (Hyclone).
RT-PCR and real-time quantitative PCR
Tumor samples were snap-frozen in liquid nitrogen. RNAs from biopsies or from cell lines were isolated using the Trizole extraction kit (Gibco BRL). A total of 5 mg of total RNA was reverse transcribed using oligodT (Roche) in a final volume of 25 ml using Superscript II (Invitrogen). After reverse transcription, 2 ng cDNA was used for real-time quantitative PCR, performed with a Lightcycler and the SYBR Green fast start kit (Roche, Germany). Primers used in real-time PCR and specific for both human and mouse sequences were as follows: N-cadherin forward 5 0 -GGCAGAAGAGAGACTGGGTC-3 0 and reverse 5 0 -GAGGCTGGTCAGCTCCTGGC-3 0 ; M-cadherin forward 5 0 -GTCATCTACAGCATCCAGGG-3 0 and reverse 5 0 -AGGAAGGCTGGCCGGTTGTC-3 0 ; R-cadherin forward 5 0 -CCGACCAGCCCCCCATGGAG-3 0 and reverse 5'-CCTGGCTTG GAGCCCTCGTCC-3 0 ; cadherin-11 forward 5 0 -CAGCTGCATTCTCCTGTGCC-3 0 and reverse 5 0 -CCTCCTTGCCCTTCTCATGG-3 0 ; GAPDH forward 5 0 -ACAGTCCATGCCATC ACTGCC-3 0 and reverse 5 0 -GCCTGCTTCACCACCTTCTTG-3 0 . The reaction contained 1 ml of Master SYBR Green I mix (Taq DNA polymerase, buffer, deoxynucleotide trisphosphate mix and SYBR Green I dye), 3 mM MgCl 2 and 0.5 mM of each primer to which 2 ml of diluted cDNA was added. A standard concentration curve was established by serial dilution of cadherins cDNA. Data were normalized using GAPDH as an index of cDNA content after reverse transcription. Amplification included initial denaturation at 951C for 8 min, and 45 cycles of denaturation at 951C for 3 s, annealing at 61-621C for 8-10 s and extension at 721C for 10-12 s performed at a temperature transition rate of 201C/ s. Fluorescence was measured at the end of each extension step. After amplification, a melting curve acquired by heating the product to 951C, cooling to and maintaining at 701C for 20 s, and then slowly (0.31C/s) heating to 951C was used to determine the specificity of PCR products, confirmed by gel electrophoresis and sequencing.
Gel electrophoresis and immunoblotting
Cell extracts were prepared as described . Protein concentration was determined with a BCA protein assay kit (Pierce). For Western blotting, equal amounts of protein (20 mg) were resolved on 8% Laemmli gel and transferred to Immobilon-P. The resulting membranes were probed with monoclonal antibodies raised against N-cadherin (1 : 250), b-catenin (1 : 500), g-catenin (1 : 200), p120 catenin (1 : 1000) (all from Transduction Laboratories), R-cadherin rat monoclonal antibody (1 : 200) (MRCD5 from Takaishi, Japan), M-cadherin polyclonal antibody generated in the laboratory, a-catenin polyclonal antibody (1 : 200; Sigma) and a-tubulin (1 : 100, P Mangeat, Montpellier, France). Membranes were processed as described .
Immunofluorescence
Cells growing onto 35-mm dishes were fixed in 3.7% formaldehyde in PBS followed by a 5 min permeabilization in 0.1% Triton X-100 in PBS and incubated in PBS containing 0.1% BSA. Anti-b-catenin, anti-g-catenin, anti-p120 catenin and anti-N-cadherin antibodies were revealed with either an Alexa Fluor 546-or an Alexa Fluor 488-conjugated goat antimouse antibody (Molecular Probes, Interchim). Anti-Mcadherin and anti-a-catenin were revealed by either an Alexa Fluor 546-or an Alexa Fluor 488-conjugated goat anti-rabbit antibody (Molecular Probes, Interchim). Cells were analysed as previously described (Gauthier-Rouviere, 1998; Charrasse et al., 2002) .
siRNA transfection and BrdU incorporation
Short interfering RNA constructs were made in pSUPER polymerase III expression vector (Brummelkamp et al., 2002) , a kind gift from R Agami (The Nederlands Cancer Institute, Plesmanlaan, the Nederlands). To suppress endogenous R-cadherin expression, oligonucleotide GATCCCCTGA CATCCCCATCCGGTACttcaagagaGTACCGGATGGGGAT GTCATTTTTGGAAA was inserted into pSUPER. Bold letters correspond to oligonucleotides 611-629 of the human R-cadherin cDNA sequence (NM-001794). As a control, M-cadherin expression, oligonucleotide GATCCCCCAG CAGCTAGGCAGTGTCAttcaagagaTGACACTGCCTAGCT GCTGTTTTTGGAAA was inserted into pSUPER. Bold letters correspond to oligonucleotides 735-753 of the mouse M-cadherin cDNA sequence (NM-007662).
RD cells were cotransfected two times with pSUPER construct and pEGFP using lipofectamine as described by the supplier (Life Technologies, Gaithersburg, MD, USA). At 4 days after the first transfection, cells were incubated with 10 mm bromodeoxyuridine (BrdU) for 3 h before fixation. Cells were stained for BrdU incorporation and for DNA. The percentage of BrdU-positive GFP-expressing cells was scored from two independent experiments.
